Wendy F. Dicicco - Jan 1, 2024 Form 3 Insider Report for Akari Therapeutics Plc (AKTX)

Role: Interim CFO
Signature: /s/ Wendy DiCicco
Stock symbol: AKTX
Transactions as of: Jan 1, 2024
Transactions value $: $0
Form type: 3
Date filed: 1/2/2024, 08:00 PM
Previous filing: Jun 22, 2023
Next filing: Jan 9, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	AKTX	Stock Option (Right to Buy)							Jan 1, 2024	Ordinary Shares, par value $0.0001 per share	5M	$0.00	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. One-hundered percent (100%) of the stock option vests and becomes exercisable on July 17, 2024 (first anniversary of the date of grant), subject to continued service with the Issuer. Notwithstanding the foregoing, should the Issuer terminate the Reporting Person for any reason other than for cause prior to the full vesting date, the stock option will continue to vest through the first anniversary of the date of grant or be accelerated, at the Issuer's option.

Content

The stock option award was granted under the Issuer's 2023 Equity Incentive Plan. One-hundered percent (100%) of the stock option vests and becomes exercisable on July 17, 2024 (first anniversary of the date of grant), subject to continued service with the Issuer. Notwithstanding the foregoing, should the Issuer terminate the Reporting Person for any reason other than for cause prior to the full vesting date, the stock option will continue to vest through the first anniversary of the date of grant or be accelerated, at the Issuer's option.